Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $27.42 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00